Gut microbiota-immune-brain interactions in chemotherapy-associated behavioral comorbidities

Kelley R. Jordan; Brett R. Loman; Michael T. Bailey; Leah M. Pyter

doi:10.1002/cncr.31584

Gut microbiota-immune-brain interactions in chemotherapy-associated behavioral comorbidities

Kelley R. Jordan, Brett R. Loman, Michael T. Bailey, Leah M. Pyter

Research output: Contribution to journal › Review article › peer-review

Abstract

Increasing scientific attention is focused on the gut-brain axis, including the ability of the gastrointestinal (GI) tract to modulate central nervous system function. Changes in the intestinal microbiome can influence affective-like behavior, cognitive performance, fatigue, and sleep in rodents and humans. Patients with cancer who are receiving chemotherapy experience similar negative behavioral changes and concurrent GI symptoms. These chemotherapy comorbidities can be long-lasting and may reduce patients' quality of life and motivation to comply with treatment. This review summarizes the clinical and preclinical evidence supporting a role for the intestinal microbiome in mediating behavioral comorbidities through peripheral immune activation in patients with cancer who are receiving chemotherapy. In addition, evidence suggesting that targeted modification of the intestinal microbiome during cancer treatment could ameliorate associated behavioral comorbidities is reviewed.

Original language	English (US)
Pages (from-to)	3990-3999
Number of pages	10
Journal	Cancer
Volume	124
Issue number	20
DOIs	https://doi.org/10.1002/cncr.31584
State	Published - Oct 15 2018
Externally published	Yes

Keywords

chemotherapy
cognition
gut microbiome
inflammation
mood

ASJC Scopus subject areas

Oncology
Cancer Research

Online availability

10.1002/cncr.31584

Library availability

Discover UIUC Full Text

Cite this

@article{0aa4d1211f7146ac8349951be8fa9a73,

title = "Gut microbiota-immune-brain interactions in chemotherapy-associated behavioral comorbidities",

abstract = "Increasing scientific attention is focused on the gut-brain axis, including the ability of the gastrointestinal (GI) tract to modulate central nervous system function. Changes in the intestinal microbiome can influence affective-like behavior, cognitive performance, fatigue, and sleep in rodents and humans. Patients with cancer who are receiving chemotherapy experience similar negative behavioral changes and concurrent GI symptoms. These chemotherapy comorbidities can be long-lasting and may reduce patients' quality of life and motivation to comply with treatment. This review summarizes the clinical and preclinical evidence supporting a role for the intestinal microbiome in mediating behavioral comorbidities through peripheral immune activation in patients with cancer who are receiving chemotherapy. In addition, evidence suggesting that targeted modification of the intestinal microbiome during cancer treatment could ameliorate associated behavioral comorbidities is reviewed.",

keywords = "chemotherapy, cognition, gut microbiome, inflammation, mood",

author = "Jordan, {Kelley R.} and Loman, {Brett R.} and Bailey, {Michael T.} and Pyter, {Leah M.}",

note = "Funding Information: The authors are supported by grants CA201681 and CA216290 from the National Institutes of Health and by the Ohio State Wex-ner Medical Center (K.R.J. and L.M.P.) and by The Research Institute at Nationwide Children{\textquoteright}s Hospital (B.R.L and M.T.B.). Funding Information: The authors are supported by grants CA201681 and CA216290 from the National Institutes of Health and by the Ohio State Wexner Medical Center (K.R.J. and L.M.P.) and by The Research Institute at Nationwide Children's Hospital (B.R.L and M.T.B.). Publisher Copyright: {\textcopyright} 2018 American Cancer Society",

year = "2018",

month = oct,

day = "15",

doi = "10.1002/cncr.31584",

language = "English (US)",

volume = "124",

pages = "3990--3999",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley & Sons, Ltd.",

number = "20",

}

TY - JOUR

T1 - Gut microbiota-immune-brain interactions in chemotherapy-associated behavioral comorbidities

AU - Jordan, Kelley R.

AU - Loman, Brett R.

AU - Bailey, Michael T.

AU - Pyter, Leah M.

N1 - Funding Information: The authors are supported by grants CA201681 and CA216290 from the National Institutes of Health and by the Ohio State Wex-ner Medical Center (K.R.J. and L.M.P.) and by The Research Institute at Nationwide Children’s Hospital (B.R.L and M.T.B.). Funding Information: The authors are supported by grants CA201681 and CA216290 from the National Institutes of Health and by the Ohio State Wexner Medical Center (K.R.J. and L.M.P.) and by The Research Institute at Nationwide Children's Hospital (B.R.L and M.T.B.). Publisher Copyright: © 2018 American Cancer Society

PY - 2018/10/15

Y1 - 2018/10/15

N2 - Increasing scientific attention is focused on the gut-brain axis, including the ability of the gastrointestinal (GI) tract to modulate central nervous system function. Changes in the intestinal microbiome can influence affective-like behavior, cognitive performance, fatigue, and sleep in rodents and humans. Patients with cancer who are receiving chemotherapy experience similar negative behavioral changes and concurrent GI symptoms. These chemotherapy comorbidities can be long-lasting and may reduce patients' quality of life and motivation to comply with treatment. This review summarizes the clinical and preclinical evidence supporting a role for the intestinal microbiome in mediating behavioral comorbidities through peripheral immune activation in patients with cancer who are receiving chemotherapy. In addition, evidence suggesting that targeted modification of the intestinal microbiome during cancer treatment could ameliorate associated behavioral comorbidities is reviewed.

AB - Increasing scientific attention is focused on the gut-brain axis, including the ability of the gastrointestinal (GI) tract to modulate central nervous system function. Changes in the intestinal microbiome can influence affective-like behavior, cognitive performance, fatigue, and sleep in rodents and humans. Patients with cancer who are receiving chemotherapy experience similar negative behavioral changes and concurrent GI symptoms. These chemotherapy comorbidities can be long-lasting and may reduce patients' quality of life and motivation to comply with treatment. This review summarizes the clinical and preclinical evidence supporting a role for the intestinal microbiome in mediating behavioral comorbidities through peripheral immune activation in patients with cancer who are receiving chemotherapy. In addition, evidence suggesting that targeted modification of the intestinal microbiome during cancer treatment could ameliorate associated behavioral comorbidities is reviewed.

KW - chemotherapy

KW - cognition

KW - gut microbiome

KW - inflammation

KW - mood

UR - http://www.scopus.com/inward/record.url?scp=85050536213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050536213&partnerID=8YFLogxK

U2 - 10.1002/cncr.31584

DO - 10.1002/cncr.31584

M3 - Review article

C2 - 29975400

AN - SCOPUS:85050536213

SN - 0008-543X

VL - 124

SP - 3990

EP - 3999

JO - Cancer

JF - Cancer

IS - 20

ER -

Gut microbiota-immune-brain interactions in chemotherapy-associated behavioral comorbidities

Abstract

Keywords

ASJC Scopus subject areas

Online availability

Library availability

Related links

Fingerprint

Cite this